Does the media refer more to KMTS or OBIO?

In the previous week, Kestra Medical Technologies had 13 more articles in the media than Orchestra BioMed. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 6 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.50 beat Kestra Medical Technologies' score of -0.01 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 2 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, CNMD or OBIO?

CONMED has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CONMED $1.37B 0.99 $47.06M $1.85 24.55 Orchestra BioMed $33.48M 10.91 -$52.70M -$0.85 N/A

Does the media favor CNMD or OBIO?

In the previous week, Orchestra BioMed had 5 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Orchestra BioMed and 1 mentions for CONMED. CONMED's average media sentiment score of 0.67 beat Orchestra BioMed's score of 0.50 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DRTS or OBIO?

In the previous week, Orchestra BioMed had 3 more articles in the media than Alpha Tau Medical. MarketBeat recorded 6 mentions for Orchestra BioMed and 3 mentions for Alpha Tau Medical. Orchestra BioMed's average media sentiment score of 0.50 beat Alpha Tau Medical's score of -0.02 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OBIO or IART?

In the previous week, Orchestra BioMed had 3 more articles in the media than Integra LifeSciences. MarketBeat recorded 6 mentions for Orchestra BioMed and 3 mentions for Integra LifeSciences. Integra LifeSciences' average media sentiment score of 0.74 beat Orchestra BioMed's score of 0.50 indicating that Integra LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integra LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OBIO or AORT?

In the previous week, Orchestra BioMed had 1 more articles in the media than Artivion. MarketBeat recorded 6 mentions for Orchestra BioMed and 5 mentions for Artivion. Orchestra BioMed's average media sentiment score of 0.50 beat Artivion's score of 0.49 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artivion 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Orchestra BioMed (OBIO) Competitors

$6.08 +0.30 (+5.19%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.05 -0.03 (-0.48%)

As of 09/18/2026 07:30 PM Eastern

Compare

OBIO vs. KMTS, CNMD, DRTS, IART, and AORT

Should you buy Orchestra BioMed stock or one of its competitors? Orchestra BioMed's main competitors and comparable companies include Kestra Medical Technologies (KMTS), CONMED (CNMD), Alpha Tau Medical (DRTS), Integra LifeSciences (IART), and Artivion (AORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Orchestra BioMed compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

In the previous week, Kestra Medical Technologies had 13 more articles in the media than Orchestra BioMed. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 6 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.50 beat Kestra Medical Technologies' score of -0.01 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	2 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has lower revenue, but higher earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	15.30	-$131.61M	-$2.67	N/A
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A

Kestra Medical Technologies has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Kestra Medical Technologies presently has a consensus target price of $28.38, indicating a potential upside of 16.15%. Orchestra BioMed has a consensus target price of $13.17, indicating a potential upside of 116.56%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Kestra Medical Technologies has a net margin of -140.43% compared to Orchestra BioMed's net margin of -184.60%. Kestra Medical Technologies' return on equity of -63.83% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

53.2% of Orchestra BioMed shares are owned by institutional investors. 5.3% of Kestra Medical Technologies shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Orchestra BioMed beats Kestra Medical Technologies on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to CONMED?

CONMED (NYSE:CNMD) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

CONMED has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

In the previous week, Orchestra BioMed had 5 more articles in the media than CONMED. MarketBeat recorded 6 mentions for Orchestra BioMed and 1 mentions for CONMED. CONMED's average media sentiment score of 0.67 beat Orchestra BioMed's score of 0.50 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CONMED currently has a consensus price target of $41.40, suggesting a potential downside of 8.85%. Orchestra BioMed has a consensus price target of $13.17, suggesting a potential upside of 116.56%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

53.2% of Orchestra BioMed shares are held by institutional investors. 0.3% of CONMED shares are held by insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CONMED has a net margin of 4.12% compared to Orchestra BioMed's net margin of -184.60%. CONMED's return on equity of 14.31% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

CONMED has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A

Summary

CONMED beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Alpha Tau Medical has higher earnings, but lower revenue than Orchestra BioMed. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A

Alpha Tau Medical presently has a consensus price target of $15.40, indicating a potential upside of 1.05%. Orchestra BioMed has a consensus price target of $13.17, indicating a potential upside of 116.56%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Alpha Tau Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -184.60%. Alpha Tau Medical's return on equity of -138.12% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-138.12%	-81.68%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Alpha Tau Medical has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Orchestra BioMed had 3 more articles in the media than Alpha Tau Medical. MarketBeat recorded 6 mentions for Orchestra BioMed and 3 mentions for Alpha Tau Medical. Orchestra BioMed's average media sentiment score of 0.50 beat Alpha Tau Medical's score of -0.02 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Orchestra BioMed beats Alpha Tau Medical on 10 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to Integra LifeSciences?

Orchestra BioMed (NASDAQ:OBIO) and Integra LifeSciences (NASDAQ:IART) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Orchestra BioMed had 3 more articles in the media than Integra LifeSciences. MarketBeat recorded 6 mentions for Orchestra BioMed and 3 mentions for Integra LifeSciences. Integra LifeSciences' average media sentiment score of 0.74 beat Orchestra BioMed's score of 0.50 indicating that Integra LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integra LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Orchestra BioMed has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Integra LifeSciences has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 3.8% of Integra LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Orchestra BioMed has higher earnings, but lower revenue than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A
Integra LifeSciences	$1.64B	0.72	-$516.47M	-$0.09	N/A

Orchestra BioMed presently has a consensus price target of $13.17, suggesting a potential upside of 116.56%. Integra LifeSciences has a consensus price target of $18.86, suggesting a potential upside of 23.90%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities analysts plainly believe Orchestra BioMed is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88

Integra LifeSciences has a net margin of -0.44% compared to Orchestra BioMed's net margin of -184.60%. Integra LifeSciences' return on equity of 18.30% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
Integra LifeSciences	-0.44%	18.30%	5.30%

Summary

Orchestra BioMed and Integra LifeSciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Artivion?

Orchestra BioMed (NASDAQ:OBIO) and Artivion (NYSE:AORT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Artivion has a net margin of -0.67% compared to Orchestra BioMed's net margin of -184.60%. Artivion's return on equity of 6.07% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
Artivion	-0.67%	6.07%	2.93%

Orchestra BioMed presently has a consensus price target of $13.17, indicating a potential upside of 116.56%. Artivion has a consensus price target of $44.83, indicating a potential upside of 91.77%. Given Orchestra BioMed's higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than Artivion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artivion has higher revenue and earnings than Orchestra BioMed. Artivion is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A
Artivion	$441.33M	2.58	$9.77M	-$0.07	N/A

In the previous week, Orchestra BioMed had 1 more articles in the media than Artivion. MarketBeat recorded 6 mentions for Orchestra BioMed and 5 mentions for Artivion. Orchestra BioMed's average media sentiment score of 0.50 beat Artivion's score of 0.49 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Artivion has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Summary

Artivion beats Orchestra BioMed on 8 of the 14 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$347.41M	$5.53B	$7.25B	$13.13B
Dividend Yield	N/A	1.79%	2.57%	12.94%
P/E Ratio	-7.15	25.11	273.81	25.39
Price / Sales	10.91	72.24	692.78	109.00
Price / Cash	N/A	32.72	77.42	51.66
Price / Book	6.40	5.74	10.45	6.33
Net Income	-$52.70M	$151.55M	$3.48B	$358.24M
7 Day Performance	-0.65%	0.66%	0.88%	1.17%
1 Month Performance	9.55%	-3.84%	-1.59%	-2.59%
1 Year Performance	149.18%	6.85%	18.08%	5.97%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	3.6226 of 5 stars	$6.08 +5.2%	$13.17 +116.6%	+142.2%	$347.41M	$33.48M	N/A	4	Analyst Forecast High Trading Volume
KMTS Kestra Medical Technologies	1.7277 of 5 stars	$25.15 -0.1%	$28.38 +12.8%	-3.1%	$1.47B	$95.13M	N/A	443	Earnings Report Analyst Forecast
CNMD CONMED	1.6683 of 5 stars	$47.23 +0.6%	$41.40 -12.3%	-11.8%	$1.41B	$1.37B	25.54	3,900	Positive News Analyst Upgrade
DRTS Alpha Tau Medical	1.2335 of 5 stars	$15.06 +1.2%	$15.40 +2.3%	+300.0%	$1.36B	N/A	N/A	121
IART Integra LifeSciences	2.9102 of 5 stars	$16.10 +2.6%	$18.86 +17.1%	-1.0%	$1.25B	$1.64B	N/A	4,427	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. KMTS, CNMD, DRTS, IART, and AORT

How does Orchestra BioMed compare to Kestra Medical Technologies?

Summary

How does Orchestra BioMed compare to CONMED?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Summary

How does Orchestra BioMed compare to Integra LifeSciences?

Summary

How does Orchestra BioMed compare to Artivion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. KMTS, CNMD, DRTS, IART, and AORT

How does Orchestra BioMed compare to Kestra Medical Technologies?

Does the media refer more to KMTS or OBIO?

Which has better valuation & earnings, KMTS or OBIO?

Which has more risk & volatility, KMTS or OBIO?

Do analysts rate KMTS or OBIO?

Is KMTS or OBIO more profitable?

Do institutionals and insiders have more ownership in KMTS or OBIO?

Summary

How does Orchestra BioMed compare to CONMED?

Which has more risk & volatility, CNMD or OBIO?

Does the media favor CNMD or OBIO?

Do analysts rate CNMD or OBIO?

Do insiders and institutionals hold more shares of CNMD or OBIO?

Is CNMD or OBIO more profitable?

Which has higher valuation & earnings, CNMD or OBIO?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Which has stronger valuation and earnings, DRTS or OBIO?

Do analysts prefer DRTS or OBIO?

Is DRTS or OBIO more profitable?

Which has more volatility & risk, DRTS or OBIO?

Do insiders and institutionals believe in DRTS or OBIO?

Does the media favor DRTS or OBIO?

Summary

How does Orchestra BioMed compare to Integra LifeSciences?

Does the media prefer OBIO or IART?

Which has more volatility and risk, OBIO or IART?

Do insiders & institutionals believe in OBIO or IART?

Which has preferable earnings & valuation, OBIO or IART?

Do analysts prefer OBIO or IART?

Is OBIO or IART more profitable?

Summary

How does Orchestra BioMed compare to Artivion?

Is OBIO or AORT more profitable?

Do analysts rate OBIO or AORT?

Do institutionals & insiders have more ownership in OBIO or AORT?

Which has higher valuation & earnings, OBIO or AORT?

Does the media prefer OBIO or AORT?

Which has more volatility and risk, OBIO or AORT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools